Zepbound requests follow the same machinery as any prior authorization, but two things are specific to it: which approved indication you are requesting under, and whether your plan has picked a different GLP-1 as its preferred agent. The second is what refuses most Zepbound requests, and it is not a judgement about the drug.
This is one part of getting a GLP-1 covered. For the full picture, see GLP-1 Insurance Coverage: The Complete Guide.
Decide which indication you are requesting under
Zepbound carries more than one approved indication, and they are assessed against different criteria. Requesting under the wrong one, or leaving it ambiguous, is a common reason a request comes back pended.
Under chronic weight management, the criteria look like any anti-obesity medication request: BMI thresholds, comorbidity where required, documented prior attempts.
Under the obstructive sleep apnea indication, the sleep study result is doing the work. The reviewer wants objective confirmation of severity, and without it the request is assessed as a weight loss request instead, which on some plans is a different answer entirely.
Confirm the current approved indications and age ranges with your prescriber, since labels are periodically expanded.
The preferred agent problem
Many plans negotiate pricing with one manufacturer and designate that product as preferred. If your plan prefers semaglutide, a Zepbound request can be refused with an instruction to try the preferred drug first. That is step therapy, it is a formulary economics decision made before anyone read your chart, and there is a formal exception process for it.
Check your plan’s formulary before the request goes in. If Zepbound carries an ST flag, your prescriber can file the exception at the same time as the authorization rather than waiting for a predictable refusal.
What the request needs
- Height, weight and BMI measured at a recent clinical visit
- Coded diagnoses, with the qualifying comorbidity where BMI falls in the lower band
- For the sleep apnea route, the sleep study report establishing severity
- Documented prior weight management attempts with dates, duration and outcomes
- A specific medical necessity statement, referencing your circumstances rather than generic language
- If a preferred agent exists, the grounds for an exception: previously tried, contraindicated, or expected to be ineffective
Vials and pens are not interchangeable to your plan
Authorizations attach to a specific product code. Single-dose vials and autoinjector pens are separate products, and an approval covering one does not automatically cover the other.
The same applies when you move up a dose strength during titration. Ask the plan whether your authorization covers the exact presentation and strength you will be collecting, because a valid authorization can still produce a rejected claim at the counter.
If you are switching from another GLP-1
Document the previous drug properly: what it was, the dose reached, how long you took it, and why it was stopped. Inadequate response and intolerance are both legitimate grounds, and both need specifics rather than a summary.
That record is also exactly what a step therapy exception needs, so assembling it once serves both purposes.
If your plan names a different GLP-1 as preferred, expect a refusal and read how to file a step therapy exception before submitting. The documentation itself is the same as any request, set out in what your prescriber has to submit.
Frequently asked questions
Is Zepbound harder to get approved than Wegovy?
Neither is inherently harder. What decides it is which product your plan prefers, and that varies between plans and changes at plan year boundaries.
My plan covers Mounjaro but not Zepbound. Why?
They share an active ingredient but carry different approved indications, and plans treat them as separate products with separate criteria.
Can I request under both indications at once?
Your prescriber should lead with the one best supported by your documentation. Ambiguity tends to slow the review rather than broaden it.
Do I need a sleep study before requesting?
Only if you are requesting under the sleep apnea indication, in which case yes, the objective result is the evidence.
How long does approval last?
Authorization periods vary by plan. Your approval letter states the end date, and renewal is assessed against continuation criteria.
What if my plan switches preferred agents mid-year?
It happens at plan year boundaries and occasionally within one. Continuity provisions sometimes apply for people already established on a drug, so ask specifically rather than assuming.